(Reuters) - WASHINGTON, July 27 - The effectiveness of Biogen Idec and Elan Corp.'s drug Tysabri in Crohn's disease is not clearly different from other approved therapies, U.S. drug reviewers said in documents released on Friday ahead of an advisory panel meeting.
The companies are seeking approval to market the multiple sclerosis drug for Crohn's, a bowel disorder.
Read more at Reuters.com Government Filings News
The companies are seeking approval to market the multiple sclerosis drug for Crohn's, a bowel disorder.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment